Cinitapride

• UNSPSC Description:

  Cinitapride is a nonselective 5-HT1 and 5-HT4 receptors agonist and a 5-HT2 and D2 antagonist. Cinitapride can be used in functional dyspepsia (FD) and gastroesophageal reflux disease (GERD) research[1].

• Target Antigen:

  5-HT Receptor; Dopamine Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/cinitapride.html

• Purity:

  98.24

• Solubility:

  DMSO : 20.83 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C(NC1CCN(CC2CC=CCC2)CC1)C3=CC([N+]([O-])=O)=C(N)C=C3OCC

• Molecular Weight:

  402.49

• References & Citations:

  [1]Du Y, et al. Efficacy and safety of cinitapride in the treatment of mild to moderate postprandial distress syndrome-predominant functional dyspepsia. J Clin Gastroenterol. 2014 Apr;48(4):328-35.|[2]Alarcón de la Lastra C, et al. Effects of cinitapride on gastric ulceration and secretion in rats. Inflamm Res. 1998 Mar;47(3):131-6.|[3]Alarcón-de-la-Lastra Romero C, et al. Cinitapride protects against ethanol-induced gastric mucosal injury in rats: role of 5-hydroxytryptamine, prostaglandins and sulfhydryl compounds. Pharmacology. 1997 Apr;54(4):193-202.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 3

• CAS Number:

  66564-14-5